Star Combo Pharma (ASX:S66) Total Long-Term Assets: A$22.47 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:S66 Star Combo Pharma Ltd ASX:S66
35 GF Score
Price A$0.13
GF Value A$0.13
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Star Combo Pharma Total Long-Term Assets?

Star Combo Pharma ASX:S66 35 Total Long-Term Assets is A$22.47 Mil as of Dec. 2025. GuruFocus rates ASX:S66 with a GF Score™ of 35/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Star Combo Pharma's Total Long-Term Assets for the quarter that ended in Dec. 2025 was A$22.47 Mil.

Star Combo Pharma Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Star Combo Pharma's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Star Combo Pharma Total Long-Term Assets Chart

Star Combo Pharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only 24.50 24.36 24.12 24.46 22.66

Star Combo Pharma Semi-Annual Data
Jun17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.35 24.46 23.68 22.66 22.47
ASX:S66
35GF Score
Star Combo Pharma Ltd ASX:S66
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Star Combo Pharma Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of A$22.47 Mil mean?
Star Combo Pharma (ASX:S66) has a Total Long-Term Assets of A$22.47 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Star Combo Pharma and its competitors.
Is Star Combo Pharma's Total Long-Term Assets too high?
Star Combo Pharma's current Total Long-Term Assets is A$22.47 Mil. Overall, Star Combo Pharma has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's Total Long-Term Assets compare to PG and CL?
Star Combo Pharma's Total Long-Term Assets of A$22.47 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Consumer Packaged Goods company?
A good Total Long-Term Assets depends on the Consumer Packaged Goods industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Star Combo Pharma and its competitors. Star Combo Pharma's current Total Long-Term Assets is A$22.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.13 — trading right at its estimated fair value. The current Total Long-Term Assets is A$22.47 Mil. Star Combo Pharma's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current Total Long-Term Assets is A$22.47 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Star Combo Pharma (ASX:S66) Overvalued in 2026?

Based on GuruFocus' analysis, Star Combo Pharma stock appears to be undervalued. The current stock price of A$0.13 is trading 0% below its estimated GF Value™ of A$0.13. GuruFocus considers Star Combo Pharma to be Fairly Valued.

Key valuation signals for ASX:S66:

  • Total Long-Term Assets: A$22.47 Mil
  • GF Value™: A$0.13 vs. price of A$0.13 (0% below fair value)
  • GF Score™: 35/100 with 2 warning signs

No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Star Combo Pharma Business Description

Address 171 - 177 Woodpark Road, Smithfield, Sydney, NSW, AUS, 2164
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
35GF Score

Get the complete analysis for ASX:S66

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13
Price
A$0.13
GF Value